Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report

被引:0
|
作者
Shima, Hisato [1 ,2 ]
Nishitani, Masaaki [3 ]
Izaki, Hirofumi [4 ]
Minakuchi, Jun [1 ]
机构
[1] Kawashima Hosp, Kidney Dis, Tokushima, Japan
[2] Kamei Hosp, Nephrol & Hypertens, Tokushima, Japan
[3] Kawashima Hosp, Urol, Tokushima, Japan
[4] Tokushima Prefectural Cent Hosp, Urol, Tokushima, Japan
关键词
tolvaptan; nephrolithiasis; transurethral lithotripsy; acute kidney injury; autosomal dominant polycystic kidney disease; CALCULI;
D O I
10.7759/cureus.62597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 61 -year -old asymptomatic female with autosomal dominant polycystic kidney disease (ADPKD) on tolvaptan therapy was hospitalized for acute kidney injury (AKI). Nephrolithiasis had already been diagnosed; however, the patient had not undergone any interventions. She also presented with hyponatremia possibly caused by overhydration. Because the estimated glomerular filtration rate (eGFR) decline was significantly higher than the predicted rate, we considered a possible case of postrenal AKI and examined computed tomography (CT), which revealed left hydronephrosis with a 9.4 -mm ureteric stone at the level of L3/L4. We restricted fluid intake, which resulted in an increase in sodium levels. She was treated with transurethral lithotripsy (TUL) twice, which successfully improved her kidney function. Although the serum sodium levels increase because of aquaresis in almost all patients treated with tolvaptan, our case was unique in that the patient presented with hyponatremia. We should pay more attention to the periodical follow-up of nephrolithiasis in addition to the increase in total kidney volume and decide the appropriate time to treat nephrolithiasis depending on the case. We should also keep in mind that ADPKD patients have a high frequency of nephrolithiasis and, even if asymptomatic, investigate urinary tract obstruction and hydronephrosis in case of AKI.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
    Kunizawa, Kyohei
    Hoshino, Junichi
    Mizuno, Hiroki
    Suwabe, Tatsuya
    Sumida, Keiichi
    Kawada, Masahiro
    Yamanouchi, Masayuki
    Sekine, Akinari
    Hayami, Noriko
    Hiramatsu, Rikako
    Hasegawa, Eiko
    Sawa, Naoki
    Takaichi, Kenmei
    Shibata, Shigeru
    Ubara, Yoshifumi
    CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2018, 8 (01): : 62 - 69
  • [2] A Case Report of Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease in the Era of Tolvaptan
    Guerra-Torres, Xavier E.
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (03) : 284 - 290
  • [3] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Gillian M. Keating
    Drugs, 2015, 75 : 1797 - 1806
  • [4] An update on tolvaptan for autosomal dominant polycystic kidney disease
    Poch, E.
    Rodas, L.
    Blasco, M.
    Molina, A.
    Quintana, L.
    DRUGS OF TODAY, 2018, 54 (09) : 519 - 533
  • [5] Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease
    Mufti, Uwais B.
    Nalagatla, Sarath K.
    JOURNAL OF ENDOUROLOGY, 2010, 24 (10) : 1557 - 1561
  • [6] Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
    Zhou, Li
    Tian, Yan
    Ma, Liang
    Li, Wen-Ge
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (31) : 11500 - 11507
  • [7] The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
    Tomoyuki Kawada
    Clinical and Experimental Nephrology, 2016, 20 : 147 - 148
  • [8] The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
    Kawada, Tomoyuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 147 - 148
  • [9] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [10] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice
    Hines, Cheryl B.
    Hooper, Gwendolyn L.
    Collins-Yoder, Angela
    NEPHROLOGY NURSING JOURNAL, 2020, 47 (02) : 145 - 150